The IBD Observation Study

Currently Recruiting

14 Aug 2026 to 12 Sep 2026

Up to $2,650

Melbourne, Australia

The study drug is being developed to help people with inflammatory bowel disease (IBD). IBD causes ongoing inflammation in the digestive system and includes conditions like Crohn’s disease, ulcerative colitis, and indeterminate colitis. 

Apply now Speak with us

Join our clinical trial

The study drug is being developed to help people with inflammatory bowel disease (IBD). IBD causes ongoing inflammation in the digestive system and includes conditions like Crohn’s disease, ulcerative colitis, and indeterminate colitis. The study explains that there is still a real need for better treatments because current medicines don’t cure IBD, and many people either don’t respond well or stop responding over time. Inflammatory bowel disease (IBD) doesn’t currently have a cure. Medicines can help control symptoms and reduce inflammation, but many people don’t get enough relief, or their treatment stops working over time. 

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions

Nucleus Network - Image

Why participate?

Many people with IBD continue to have ongoing symptoms or develop complications such as a higher risk of certain cancers, low bone strength, anemia, or nutritional problems. Current medicines can also cause side effects. Because of this, there is a strong need for new treatments that address the underlying cause of IBD, not just its symptoms. 

Trial details

Ethics

The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.

Additional eligibility

  • Prescription medications must be complete 7 days prior to admission 
  • Non-smokers or smoking less than 10 cigarettes per week  
  • Not pregnant or breastfeeding   
  • Willing to follow contraception guidelines (If applicable)  
  • Willing and able to attend all study visits and follow instructions   

Study duration

2-night in-clinic stay and 3 follow-up visits

Are you a match?

Age

18 - 64 years old

Remuneration

Up to $2,650 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

2 nights, 3 clinic visits

Register Your Interest for The Passage Study

Thank you for your interest in participating in a clinical trial. This study is evaluating an investigational drug that may help address conditions involving inflammation and tissue scarring.

 The study is scheduled for March 2026, and you’ll need to be available during that time.

This form takes 2–3 minutes to complete, and your information will remain confidential, used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1300 590 848 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow participants who are (social) smokers.

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Referral Information



Consent to Information Use and Future Contact